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Sigma 1 receptor 
A B S T R A C T   
Sigma-1 receptors (σ1R) have been implicated in several pain pathways. We assessed the implication of σ1Rs in 
the development of intestinal inflammation and inflammation-associated referred hypersensitivity in a model of 
colitis in σ1R knockout (KO) mice. Colitis was induced with dextran sulfate sodium (DSS) in wild type (WT) and 
σ1R KO mice. The development of referred mechanical hypersensitivity (von Frey test) was assessed. Colonic and 
spinal changes in expression of immune- and sensory-related markers were also investigated (RT-qPCR/Western 
blot). Absence of σ1Rs had little impact in colitis generation and progression, although during the chronic phase a 
reduction in edema and a down-regulation of iNOS gene expression was observed. In σ1R KO mice, inflammation- 
associated hypersensitivity was significantly attenuated (paw) or completely prevented (abdomen). During co-
litis, in WT mice, changes in the colonic expression of nociceptive markers were observed during the acute and 
chronic phases of inflammation. Although σ1R KO mice showed similar regulation in the acute phase, an 
attenuated response was observed during the chronic phase of colitis. These differences were especially relevant 
for CB2 and TRPV1 receptors, which could play an important role in σ1-mediated regulation of sensitivity. No 
changes were detected on ERK phosphorylation at the level of the lumbosacral spinal cord. In summary, intes-
tinal inflammation-associated referred hyperalgesia was reduced (paw) or absent (abdomen) in σ1R KO mice, 
thus confirming an important role for σ1R in the development of colitis-associated hypersensitivity. These results 
identify σ1Rs as a possible therapeutic target for the treatment of hypersensitivity associated to intestinal 
inflammation.   
1. Introduction 
Evidences suggest that inflammation within the gastrointestinal 
tract, even at a low degree, and the presence of visceral and somatic 
hypersensitivity are associated phenomena. Indeed, inflammatory con-
ditions of the gastrointestinal tract, such as inflammatory bowel disease 
(IBD), are associated to both somatic and visceral hypersensitivity [1,2]. 
Moreover, irritable bowel syndrome (IBS), the main functional gastro-
intestinal disorder, has been associated to a low degree of intestinal 
inflammation and has altered colonic sensitivity with increased 
perception as key manifestations [3,4]. Additionally, changes in somatic 
sensitivity, characterized by referred hypersensitivity, have also been 
observed in states of intestinal inflammation [5,6]. In this context, in-
testinal inflammation and the associated state of hypersensitivity are 
still areas of medical needs, without fully effective therapeutic 
approaches. 
During the last years, several targets have been explored as potential 
treatments of visceral pain arising from the gut. However, at the current 
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time there are no effective treatments for this type of pain. Some efforts 
have been directed towards the validation of analgesic treatment posi-
tively validated against somatic pain, although the differences between 
these pain modalities might be relevant in this respect. In recent years, 
sigma-1 receptors (σ1Rs) have been implicated in pain mechanisms and 
suggested as potential pharmacological target for the treatment of so-
matic pain. σ1R is a neuromodulatory, ligand-regulated membrane 
protein chaperone that exerts its functions through multiprotein com-
plex assembly [7,8]. The relation of σ1 Rs and pain was first suggested by 
studies showing a relationship between σR systems and opioid-mediated 
analgesia [9,10]. Evidences indicate that σ1R ligands fail to modify 
normal pain responses by themselves, as demonstrated in classical 
models of thermal and mechanical acute nociception [11,12]. However, 
σ1R ligands seem to play a key role in modulating pain behavior in states 
of sensitization and chronic pain conditions [13]. In this respect, recent 
studies show that both central and peripheral pharmacological blockade 
of σ1Rs could be an effective option to treat inflammatory pain [13–16]. 
As it relates to visceral pain responses arising from the gut, evidences 
indicate a potential modulatory role for σ1Rs. In this sense, σ1Rs selec-
tive antagonists were effective preventing visceral pain-related re-
sponses elicited by intracolonic capsaicin in mice [17]. 
Taking into account these considerations, the aims of the present 
study were to assess the potential modulatory role of σ1Rs on intestinal 
inflammation and the development of inflammation-associated hyper-
sensitivity in a murine model of dextran sulfate sodium (DSS)-induced 
colitis. With this objective, we assessed the development of colitis and 
inflammation-associated visceral and somatic hypersensitivity in σ1R 
knockout (KO) mice compared to wild-type (WT) animals. Moreover, 
colitis-associated changes in peripheral (colon) and central (spinal cord) 
sensory-related markers implicated in pain processing and sensitization 
were also assessed. 
2. Materials and methods 
2.1. Animals 
Male WT C57BL/6J mice (n = 28, Charles River Laboratories, Lyon, 
France) and σ1R KO C57BL/6J mice (n = 31, Esteve Pharmaceuticals S. 
A., Barcelona, Spain), both aged 6-weeks at the time of starting the 
studies, were used. Mice were group-housed in standard cages (four-six 
mice per cage) and maintained under standard condition of photoperiod 
(12:12 h light-dark cycle) and climate (20–22 ºC, 40–70% humidity), 
with ad libitum access to a standard diet and tap water, except when 
receiving DSS. Mice were allowed to acclimatize to the animal facility 
for at least 1 week before starting the studies. All procedures were 
approved by the Ethical Committee of the Universitat Autònoma de 
Barcelona (protocols 3039 and 3957) and the Generalitat de Catalunya 
(protocols 8823 and 9915). 
2.2. Colitis induction 
A solution of DSS (45 kDa; 2% concentration in water; TdB Consul-
tancy AB, Uppsala, Sweden) was used to induce colitis. Fresh DSS so-
lutions were prepared daily during the 5-day treatment period (from 
experimental day 0 to day 5). Following this protocol animals develop 
an acute colitis (7–8 days after starting DSS exposure) that progresses to 
chronicity. Similar protocols have been used in previous studies in mice 
to induce colitis [18–22]. Normal tap water was used as the control 
treatment. 
2.3. Evaluation of referred mechanical hypersensitivity: von Frey test 
Animals were placed into compartment enclosures in a test chamber 
with a framed metal mesh floor through which von Frey monofilaments 
(bending force range from 0.04 to 2 g; North Coast Medical, Inc.; Gilroy, 
CA, USA) were applied for pain assessment. Pain sensitivity was 
evaluated after a 30 min habituation period to the testing environment. 
Referred pain was assessed in two separate regions, the abdominal wall 
and the hind paw. When assessing sensitivity of the abdominal wall the 
perianal and external genitalia areas were avoided, concentrating the 
mechanical stimulation on the lower and mid abdomen, as previously 
reported [17,23]. Paw sensitivity was quantified by measuring the hind 
paw withdrawal response to punctate mechanical stimulation, as pre-
viously described [24,25]. In all cases, pain thresholds were determined 
using the up-down method paradigm and represent the mechanical 
stimulus that produces 50% of maximal response [26]. Data obtained 
were normalized to a baseline measurement (taken as 1), taken 24 h 
before starting the experimental procedures (Fig. 1). All measurements 
were performed twice, with a 30-min recovery period in between, by 
two independent investigators. The mean values of the two observations 
were taken, for each animal, as the measure of pain sensitivity. 
2.4. Experimental protocol 
WT and σ1R KO mice were randomly divided into 2 experimental 
groups per genotype (n = 12–19 per group). In a random assignment, 
the experimental groups received tap water or a solution of 2% DSS 
during a 5-day period (days 0–5). After DSS/water exposure, all animals 
received normal water and were allowed to recover for a 2-day (acute 
inflammatory phase) or a 16-day period (chronic inflammatory phase) 
before euthanasia. Individual body weight, general state and the pres-
ence of clinical signs were assessed on a daily basis throughout the 
study. Von Frey test was performed 4 times during the experimental 
procedure: the day before starting the administration of DSS (taken as a 
basal measure of sensitivity, day − 1), at approximately half of time of 
DSS exposure (day 3), at the end of acute inflammatory phase (day 7) 
and at the end of the experiment (chronic inflammatory phase, day 21). 
Animals were euthanized for the collection of samples immediately after 
the last von Frey test evaluation (see below). See Fig. 1 for details of the 
experimental protocol. 
2.5. Samples collection 
Immediately after the last von Frey test (days 7 or 21, for the acute 
and chronic phase, respectively), mice were deeply anesthetized with 
isoflurane (Isoflo; Esteve, Barcelona, Spain) and euthanatized by 
exsanguination through intracardiac puncture followed by cervical 
dislocation. Thereafter, a medial laparotomy was performed, the ceco- 
colonic region localized and the cecum and colon dissected. After-
ward, two tissue samples from the proximal-middle colon (about 1.5 cm 
each) were collected. A sample was frozen immediately in liquid nitro-
gen and a second sample was fixed in 4% paraformaldehyde. After an 
overnight fixing, tissues were paraffin embedded and 5-µm-thick sec-
tions were obtained. The lumbar enlargement (L3-S2) of spinal cord was 
dissected and frozen immediately in liquid nitrogen. Frozen samples 
were stored at − 80 ºC until analysis. In addition, the liver, the adrenal 
glands, the thymus, and the spleen were dissected and weighed. Serum 
was obtained by centrifugation of blood samples (15 min, 10,000×g, 
4 ºC) and maintained at − 80 ºC until analysis. 
2.6. Clinical and macroscopic assessment of inflammation 
Clinical assessment of inflammation included daily monitoring of 
body weight, appearance of feces and general health condition [19]. A 
score (0− 8) was assigned for health condition (including hunch posture, 
piloerection, fecal consistency and aspect of the anus); where 0 indicates 
normal activity/fur/normal feces/normal anus, 1 indicates abnormal 
gait/bristly fur/wet/watery feces/wet anus and 2 indicates prostrated 
animal/dirty fur/watery diarrhea/bloody rest on anus. At necropsy, the 
macroscopic appearance of the colon was scored following previously 
published procedures [19]. Briefly, the presence of inflammatory signs 
(inflammatory score): consistency of fecal contents (score 0–3); presence 
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of visible fecal blood (score 0–3); evidence and extent of edema (0− 3); 
wall thickness (0− 3); tissue stiffness (0− 2) and presence of ulcerations 
(0− 1) were assessed; resulting in a maximum total score of 15. 
2.7. Histological studies 
For histological examination, hematoxylin-eosin-stained sections 
from the colon were obtained following standard procedures. A histo-
pathological score (ranging from 0, normal, to 12, maximal alterations) 
was assigned to each animal [27]. Specifically, parameters scored 
included: epithelial structure (0: normal; 1: mild alterations of the villi; 
2: local villi destruction and/or fusion; 3: generalized villi destruction 
and/or fusion), structure of the crypts (0: normal; 1: mild alterations of 
the crypts; 2: local destruction of the crypts; 3: generalized destruction 
of the crypts), presence of edema (0: normal; 1: mild local edema in 
submucosa and/or lamina propria; 2: moderate diffuse edema in sub-
mucosa and/or lamina propria; 3: severe generalized edema in submu-
cosa and/or lamina propria), and presence of inflammatory infiltrate (0: 
normal; 1: mild localized infiltrate; 2: mild generalized infiltrate; 3: 
severe generalized infiltrate). Scoring was performed on coded slides by 
two independent researchers and the mean value of the two scores was 
taken as the final score per animal. 
2.8. Serum haptoglobin 
Serum concentrations of haptoglobin were determined using a 
commercial ELISA kit, following manufacturer’s instructions (sensi-
tivity; 0.005 mg/ml; intraassay variability: 5.3–6.3%; interassay vari-
ability: 4.1–5.7%; “PHASE” TM Haptoglobin Assay; Tridelta 
Development Limited, Maynooth, County Kildare, Ireland). 
2.9. Gene expression using Quantitative Reverse Transcription-PCR 
Total RNA was extracted from frozen tissue samples using TRI re-
agent with Ribopure Kit (Ambion/Applied biosystems, Foster City, CA, 
USA). RNA was purified by via precipitation with lithium chloride [28]. 
Later, a two-step quantitative real-time PCR (RT-qPCR) was performed. 
RNA samples were converted into cDNA using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). The PCR reaction 
mixture was incubated on the Bio-Rad CFX384 Touch Real-Time PCR 
Detection System (Bio-Rad). All samples were assayed in triplicate. The 
cycle thresholds for each sample were obtained and data were analyzed 
using the comparative Ct method (2-ΔΔCt) with the WT vehicle group 
serving as the calibrator [29]. TaqMan® gene expression assays (hy-
drolysis probes, Applied Biosystems) used included: cannabinoid re-
ceptors 1 (CB1) (Mm01212171_s1) and 2 (CB2) (Mm00438286_m1), 
interferon γ (INF-γ) (Mm01168134_m1), interleukin 1β (IL-1β) 
(Mm00434228_m1), 6 (IL-6) (Mm00446190_m1), 10 (IL-10) 
(Mm00439614_m1) and 12 (IL-12p40) (Mm00434174_m1), µ-opioid 
receptor (MOR) (Mm01188089_m1), nerve growth factor (NGF) 
(Mm00443039_m1), nitric oxide synthase 2 (inducible, iNOS) 
(Mm00440502_m1), prostaglandin-endoperoxide synthase (Cyclo-
oxygenase 2, COX-2) (Mm00478374_m1), protease activated receptor 2 
(PAR2) (Mm00433160_m1), serotonin transporter (SERT) 
(Mm00439391_m1), transient receptor potential vanilloid 1 (TRPV1) 
(Mm01246302_m1) and 3 (TRPV3) (Mm00455003_m1), tryptophan 
hydroxylase 1 (TPH1) (Mm00493794_m1) and σ1 receptor (σ1R) 
(Mm00448086_m1). β-2-microglobulin (β2m) (Mm00437762_m1) was 
used as endogenous reference gene. 
2.10. Protein expression using Western blot 
Dissected spinal cord samples were homogenized by sonication in 
radioimmunoprecipitation assay (RIPA) buffer and the supernatant was 
obtained. Equal amounts of protein (30 µg) were fractionated by 10% 
(w/v) SDS–PAGE and transferred onto a polyvinylidene difluoride 
membrane, blocked with 5% non-fat dry milk in Tris–Tween 20-buffered 
Saline (T–TBS) for 1 h. Membranes were then incubated overnight at 4 
ºC in 1% non-fat dry milk in T–TBS with rabbit primary polyclonal an-
tibodies recognizing the mitogen-activated protein kinase (MAPK, total 
ERK ½, 1:30000) or mouse monoclonal antibodies recognizing the 
activated MAPK (diphosphorylated MAPK, pERK ½, 1:1000). Rabbit 
polyclonal anti-GAPDH antibody (1:20000) or mouse monoclonal anti- 
GAPDH antibody (1:80000) were used as a loading control, respec-
tively. After washing with T–TBS, the blots were incubated for 1 h with 
horseradish peroxidase–conjugated goat anti-rabbit IgG (1:4000) or 
goat anti-mouse IgG (1:2000). The immunoreactive bands were detected 
by a peroxidase reaction using an enhanced chemiluminescence method 
(WesternSure® PREMIUM Chemiluminescent Substrate, Li-cor) and 
CDiGit ® Blot Scanner (Li-cor). All antibodies were obtained from Sig-
ma–Aldrich Co. (Madrid, Spain). Quantification was realized with Image 
Studio™ Lite Software. 
2.11. Statistical analysis 
Data are expressed as mean ± SEM. A robust analysis (one iteration) 
was used to obtain mean ± SEM for RT-qPCR data. Data were analyzed 
by one-, two or three-way ANOVA, as appropriate, followed, when 
necessary, by a Bonferroni’s multiple comparisons test. Data were 
considered statistically significant when P < 0.05. Statistical analyses 
were performed using GraphPad Prism version 7.0 (GraphPad Software, 
La Jolla, CA, USA) or SPSS program (version 17 for Windows, IBM, 
Madrid, Spain). 
3. Results 
3.1. Colitis development in WT and σ1R KO mice 
Regardless the genotype considered, mice receiving water showed a 
steady and linear increase in body weight, without clinical signs 
Fig. 1. Schematic representation of the experimental protocols followed in the study. VF: von Frey test.  
S. López-Estévez et al.                                                                                                                                                                                                                          
Biomedicine & Pharmacotherapy 143 (2021) 112126
4
throughout the experimental period (Fig. 2). Conversely, in animals 
exposed to DSS, body weight loss was observed from experimental day 
6, with a peak reduction between days 9 and 10, and a progressive re-
covery up to day 21, although without reaching the body weight of 
control animals not exposed to DSS. No differences in this pattern were 
observed between σ1R KO and WT mice. In animals exposed to DSS, 
clinical signs (mainly bristly fur, wet/watery feces and wet anus) 
consistent with the development of a colitic state appeared with similar 
temporal pattern to that described for body weight changes, reaching a 
maximum at day 9 and disappearing completely by the end of the 
experimental time (Fig. 2). No genotype-related differences were 
observed in the incidence and severity of clinical signs. Water intake was 
similar across experimental groups (data not shown). 
At necropsy, WT mice receiving DSS showed macroscopic signs of 
colonic inflammation, both at the acute and chronic phase, character-
ized by shortening in length and an increase in its relative weight 
(P < 0.05 vs. WT mice receiving water; Fig. 3A). Similar changes were 
observed in σ1R KO mice. A slight attenuation in inflammation-related 
parameters was observed in σ1R KO mice when compared to WT, 
although statistical significance was not achieved (Fig. 3A). 
Microscopic analysis of colonic tissue samples showed a normal 
histological structure in control animals. Regardless the genotype 
considered, exposure to DSS led to a similar significant increase in his-
topathological scores (Fig. 3B). Colonic alterations were attenuated 
during the chronic phase, however statistical significance was only 
achieved for σ1R KO mice (P < 0.05 vs. σ1R KO mice during the acute 
phase). The improvement observed in σ1R KO mice was mainly associ-
ated to a reduction in the presence of edema (statistically significant 
interaction by genotype and time on the presence of edema -P < 0.05-, 
Fig. 3B). Regardless of the phenotype considered, no significant changes 
were observed for the relative weight of body organs (data not shown). 
The acute phase protein haptoglobin showed a similar increase in 
WT and σ1R KO animals during acute inflammation (P < 0.05 vs. 
respective control). Haptoglobin levels showed a tendency towards 
normalization during the chronic phase, although they remained 
significantly increased when compared to non-inflamed animals 
(Fig. 3C). 
3.2. Inflammatory markers are differentially regulated in WT and σ1R 
KO mice during colitis 
In control conditions, independently of the genotype and time of 
measurement, expression of the cytokines assessed was detectable in all 
colonic samples. In WT mice, colitis was associated to an up-regulation 
of the expression of the pro-inflammatory cytokines INF-γ, IL-1β and IL- 
6, which was particularly evident during the acute phase of inflamma-
tion and persisted during the chronic phase, although relatively atten-
uated (in all cases P < 0.05 vs WT control mice, Fig. 4). No significant 
changes were observed in the local expression of IL-12p40 and IL-10. 
In σ1R KO mice an up-regulation of INF-γ, IL-1β and IL-6 was 
observed during the acute phase of inflammation (all P < 0.05 vs. non- 
inflamed animals), but expression levels were basically normalized 
Fig. 2. Time-related changes in relative body weight (% change from day 0, taken as 100%, upper panel) and clinical signs (lower panel) in the different experi-
mental groups. Data are mean ± SEM (n = 12–18). The DSS-treatment period is indicated by the grey area. 
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during the chronic phase (all P > 0.05 vs. non-inflamed animals, Fig. 4). 
A significant up-regulation of IL-10 expression was detected in σ1R KO 
mice during the chronic phase (P < 0.05 vs. other experimental groups). 
Similarly to that observed in WT animals, no changes were observed in 
the expression of IL12p-40. 
Colonic expression of iNOS was up-regulated in acute colitic WT 
mice, although with relatively high variability (P < 0.05 vs control WT 
group). This up-regulation persisted during the chronic phase, although 
with some attenuation, (Fig. 5). In σ1R KO mice, iNOS expression was 
up-regulated during acute colitis, while returning during the chronic 
phase to the levels detected in non-inflamed animals (Fig. 5). 
In colitic WT mice, 3 out of 5 animals showed COX-2 expression 
levels above the mean expression of the control group, during either the 
acute or the chronic phase, thus suggesting a tendency for COX-2 up- 
regulation during colitis. However, no statistical significance was ach-
ieved, probably because of the high interindividual variability observed. 
No expression changes were observed in σ1R KO mice, regardless the 
inflammatory phase considered (Fig. 5). 
3.3. Colitis-associated mechanical hypersensitivity is attenuated in σ1R 
KO mice 
Baseline (experimental day − 1) abdominal and paw withdrawal 
thresholds during the von Frey test were similar in WT and σ1R KO mice 
(Fig. 6). 
In healthy WT mice, abdominal and somatic mechanical sensitivity 
was stable throughout the experimental time (Fig. 7). However, in WT 
animals receiving DSS a reduction in the withdrawal thresholds was 
observed from experimental day 3 throughout experimental day 21, 
indicating the development of mechanical hypersensitivity (in all cases 
P < 0.05 vs. control group). 
As it relates to σ1R KO mice, mechanical thresholds were stable in 
colitic animals and showed only a transitory reduction in experimental 
day 7 for abdominal sensitivity (P < 0.05 vs. control group), with a re-
turn towards basal sensitivity on experimental day 21; whereas no 
changes were observed for somatic sensitivity (Fig. 7). 
Fig. 3. Assessment of colonic inflammation at the time of necropsy in the different experimental groups. (A) Macroscopic scores. (B) Histopathological scores: 
inflammatory infiltrate, edema, state of the crypts and epithelial structure. (C) Plasma concentrations of the acute phase protein haptoglobin. Data are mean ± SEM 
of 6–10 animals per group. *P < 0.05 vs. respective control group; #P < 0.05 vs. respective acute DSS-treated group. 
Fig. 4. Heat map of the relative mRNA expression of colonic pro- (INF-γ, IL-1β, IL-6 and IL-12p40) and anti-inflammatory cytokines (IL-10) in the different 
experimental groups. Each vertical line, with a number, corresponds to an individual animal within the corresponding experimental group. 
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3.4. Expression of colonic sensory-related markers is modulated during 
DSS-induced colitis 
Expression of the sensory-related markers assessed was detected in 
all colonic samples, except for σ1R, that, as expected, was only found in 
WT animals. In healthy animals, expression levels of the markers 
assessed were comparable, regardless the genotype considered. 
During colitis in WT mice, there was an overall down-regulation of 
all sensory markers analyzed when compared with non-inflamed ani-
mals. This was particularly evident during the acute phase, with a ten-
dency towards normalization during the chronic phase (Fig. 8). In 
particular, except for CB2 and PAR-2 which showed no changes, all 
analyzed markers were down-regulated during both the acute and 
chronic phases of colitis in WT mice (in all cases P < 0.05 vs. respective 
control group). In these animals, expression of σ1R was down-regulated 
during acute colitis (P < 0.05 vs. control group), returning to basal 
expression levels during the chronic phase. 
Regarding σ1R KO mice, an overall down regulation was also 
observed during the acute phase, but a trend towards baseline levels was 
observed in the chronic phase of colitis. Nevertheless, CB1, MOR and 
TPH1 showed a persistent down-regulation during both the acute and 
the chronic phase of inflammation (in all cases P < 0.05 vs. respective 
control group). On the other hand, expression of NGF, SERT, TRPV1 and 
TRPV3 in σ1R KO mice was down-regulated only during the acute phase 
of colitis (in all cases P < 0.05 vs. respective control group), while 
during the chronic phase a slight down-regulation was detected, 
although statistical significance was not achieved (Fig. 8). In σ1R KO 
mice, expression of CB2 was significantly up-regulated in the chronic 
phase of colitis. 
3.5. ERK expression within the spinal cord is not affected by colitis 
ERK protein was detected in all spinal cord samples, regardless the 
experimental group considered. Similar levels of tERK and pERK were 
detected in WT and σ1R KO mice in control conditions. During colitis, 
regardless the phase considered, no changes were observed in tERK or 
pERK content or the ratio pERK/tERK (Fig. 9). 
4. Discussion 
In the present study, we assessed the potential role of σ1Rs in the 
development of colitis and inflammation-associated changes in referred 
mechanical sensitivity using a murine model KO for σ1Rs. Results ob-
tained indicate that σ1Rs only marginally affected the development of 
intestinal (colonic) inflammation or its progression from acute to 
chronic, but they seem to play an important role in the development of 
inflammation-associated hypersensitivity. 
In WT animals, exposure to DSS led to the development of colitis with 
similar clinical, histopathological and molecular alterations to those 
previously described [18,19,30]. Moreover, we also observed that the 
inflammatory condition showed a chronification, characterized by the 
persistence over time, although with some attenuation, of the structural, 
molecular and biochemical alterations observed during the acute phase 
and a remission of the clinical signs. This chronification process co-
incides with the evolution of DSS-induced colitis previously described 
for the same strain of mice [18] and shares similarities with the quies-
cent phases of inflammatory bowel disease in humans [30]. 
In σ1R KO animals, exposure to DSS led to the induction of colitis 
with, essentially, the same characteristics as those discussed above for 
Fig. 6. Baseline abdominal (A) and paw (B) withdrawal thresholds in the von Frey test in WT and σ1R KO mice. Data are mean ± SEM of n = 6–10 mice per group.  
Fig. 5. Colonic expression of inflammatory markers: iNOS, and COX-2. Each point represents an individual animal; the horizontal bar with errors represents the 
mean ± SEM. *P < 0.05 vs. respective control group; +P < 0.05 vs. respective WT DSS-treated group. 
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WT mice. Overall, these observations suggest that σ1Rs play a minor role 
in the development of intestinal inflammation. Nevertheless, some dif-
ferences were observed between WT and σ1R mice, particularly as it 
relates to structural and molecular parameters during the chronic phase 
of colitis. Firstly, the presence of submucosal edema was significantly 
reduced in σ1R KO vs. WT mice during chronic colitis. This finding 
agrees with previous data showing a reduction in subepithelial edema in 
σ1R KO mice in a model of cyclophosphamide-induce cystitis [31] or the 
reduction in paw edema, elicited by the intraplantar injection of carra-
geenan, associated to the blockade of σ1Rs with specific antagonists [14, 
15]. Moreover, the attenuation of paw edema might implicate 
NOS-dependent mechanisms affecting vascular permeability and 
extravasation [14,15]. Interestingly, in σ1R KO mice treated with DSS, 
iNOS expression, which was moderately up-regulated in WT animals 
with colitis, showed similar expression levels as those detected in 
non-inflamed controls. This suggests that σ1Rs might regulate vascular 
permeability and extravasation, at least partially throughout 
NO-dependent mechanisms, and thus, exert some modulatory effects on 
inflammation. Additionally, in σ1R KO mice, expression of 
pro-inflammatory cytokines, as well as iNOS and COX-2, was normalized 
during the chronic phase of colitis, while remaining up-regulated in WT 
animals. Altogether, these data suggest that σ1Rs might exert a positive 
immunomodulatory action, as previously suggested in other models [14, 
31,32], likely facilitating the recovery in chronic conditions, at least as it 
relates to intestinal inflammation. 
Compelling evidences implicate σ1Rs in pain mechanisms [12]. In 
our experimental conditions, σ1R KO and WT mice showed similar 
mechanosensitivity, as determined by assessing withdrawal thresholds 
Fig. 7. Sensitivity thresholds to mechanical stimulation during DSS-induced colitis in WT and σ1R KO mice. (A) abdominal and (B) paw withdrawal thresholds in WT 
and σ1R KO mice. In all cases, mechanical sensitivity was determined in basal conditions (day − 1, d-1) and at experimental days 3 (d3),7 (d7) and 21 (d21). Data 
show normalized values (relative force) with respect to basal measurements at experimental day − 1, taken as a relative force of 1. Reductions in relative force 
indicate the development of hypersensitivity. Data are mean ± SEM of n = 6–10 mice per group. *P < 0.05 vs. d-1 of respective experimental group. 
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to the mechanical stimulation of the lower abdominal wall, likely 
reflecting responses associated to the mechanical stimulation of the 
abdominal wall and the underlying viscera (mainly intestine), or the 
hind limbs. These observations agree with previous data showing that 
σ1R KO mice perceived and responded normally to acute somatic me-
chanical nociceptive stimuli [17,24] and with pharmacological obser-
vations showing that σ1R ligands, either agonists or antagonists, have no 
effects by themselves on somatic mechanosensitivity in basal conditions 
[11,33,34]. Altogether, these results support the view that σ1Rs are not 
involved in normal pain responses. Alternatively, we cannot discard that 
compensatory mechanisms, associated to the constitutive absence of 
σ1Rs, lead to normal basal pain responses in these animals. 
Intestinal inflammation has been associated to the development of 
visceral hypersensitivity as well as referred hyperalgesia in several body 
regions, including the abdominal wall, tail and hind paws [1,5,6,35]. In 
agreement with this, results obtained here show that colitic WT mice 
showed mechanical hypersensitivity, manifested as a persistent reduction 
in the withdrawal threshold to the mechanical stimulation of the abdom-
inal wall (likely reflecting a combination of somatic hypersensitivity -from 
the abdominal wall per se- and visceral hypersensitivity of the underlying 
viscera -intestine-) and the hind limbs. Interestingly, the sensitizing effects 
of inflammation were significantly attenuated in σ1R KO mice. Indeed, in 
σ1R KO animals, paw sensitivity was not affected during colitis, while at the 
abdominal level only a transitory state of hypersensitivity was observed 
during the acute phase of colitis, with a clear tendency towards normali-
zation during the chronic phase. These observations are in agreement with 
previous data showing a reduction in behavioral responses to visceral pain 
in σ1R KO mice after intracolonic administration of capsaicin [17] or 
during cystitis [31] and the reduction of nociceptive responses associated to 
neuropathic pain [24,36,37]. Moreover, these data in σ1R KO mice further 
confirm pharmacological observations showing blockade of somatic pain 
responses by selective σ1R antagonists [14,15,25,34,38]. Altogether, these 
data strongly suggest a key involvement of σ1Rs in the development of 
inflammation-dependent referred hypersensitivity, consistent with previ-
ous reports. Moreover, taking into account the fact that the stimulation of 
the abdominal wall is likely to implicate somatic and visceral pain-related 
responses, our observations also support an implication of σ1Rs in visceral 
sensitivity. 
To further understand the mechanisms implicated in these changes 
we assessed the local (colon) expression of different sensory-related 
markers implicated in viscerosensitivity. During colitis, a general 
down-regulation of sensory markers was observed, regardless the ge-
notype considered. Thus, supporting the development of nociceptive 
alterations, at least at a molecular level, during inflammation. It is 
difficult to establish a direct correlation between gene expression 
changes of pain-related markers and pain-related responses since a 
Fig. 8. (A) Heat map of the relative mRNA expression of sensory-related markers in the different experimental groups. Note that, as expected, no σ1R expression was 
detected in σ1R KO animals. Each vertical line, with a number, corresponds to an individual animal within the corresponding experimental group. “X” denotes 
samples with no expression detected. (B) Detail of the expression changes for the mean genes modified, according to A. Each point represents an individual animal; 
the horizontal bar with errors represents the mean ± SEM. *P < 0.05 vs. respective control group; #P < 0.05 vs. respective acute control group; +P < 0.05 vs. 
respective WT group. 
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down-regulation was detected for both pro- and anti-nociceptive 
markers. Therefore, the final functional outcome is likely to depend 
upon the balance between changes in expression that favor or counteract 
pain-related mechanisms, as previously suggested for other experi-
mental conditions related to intestinal sensitivity [39,40]. Despite this, 
distinctive changes in some pain-related markers were observed in σ1R 
KO animals. Specifically, the up-regulation detected for CB2 during 
chronic colitis might be of particular significance. Given the 
anti-nociceptive effects associated to the activation of CB2 [41–43], the 
up-regulation observed might explain, at least in part, the attenuation of 
pain-related responses observed in these animals during colitis. 
The TRPV family of receptors has been related to inflammation and 
pain. In particular, TRPV1 expression has been positively correlated 
with pain severity in patients with quiescent IBD [44] and an 
up-regulation has also been observed during colonic inflammation [45], 
likely contributing to the visceral hypersensitivity observed after colitis 
[46]. In the present studies, a down regulation of TRPV1 associated with 
inflammation, either acute or chronic, was observed in WT mice, even 
though the presence of mechanical hypersensitivity. These apparently 
contradictory observations reinforce the importance of the balance be-
tween pro- and anti-nociceptive mechanisms in the final outcome as it 
relates to pain, as discussed above. Alternatively, and given the 
pro-nociceptive effects of TRPV1, a down-regulation of the receptor 
might be interpreted as a compensatory mechanism developed under 
some conditions (such as acute inflammation) to avoid abnormal 
excessive pain. Furthermore, recent studies have described interactions 
between σ1R and TRPV1 receptors [47,48], thus indicating that both 
receptors might interact during states of hypersensitivity facilitating 
pain. Indeed, σ1R antagonism results in the negative regulation of the 
protein expression of TRPV1 in the plasma membrane of sensory neu-
rons and, consequently, a decrease in nociceptive responses [47]. 
Therefore, the lack of functional σ1Rs, leading to an altered TRPV1-σ1R 
interaction might contribute to de underlying mechanisms explaining 
the absence of hypersensitivity in σ1R KO mice. 
Sensitization of pain mechanisms can occur at either peripheral and/ 
or central levels. Our results, as discussed above, suggest that peripheral 
(colonic) changes might contribute to the sensitization processes asso-
ciated to inflammation. Nevertheless, to assess the potential participa-
tion of central (spinal) sensitization, we also assessed ERK 
phosphorylation at the level of the lumbosacral spinal cord. Lower 
lumbar and upper sacral segments of the spinal cord represent the main 
site of entry to the central nervous system for sensory afferents arising 
from the colon implicated in pain responses in rodents [49]. Within the 
spinal cord, ERK phosphorylation is regarded as a key process involved 
in pain processing and sensitization. Indeed, an increase in spinal 
phosphorylated ERK (pERK) has been described in several models of 
somatic [24] and visceral pain [50]. Moreover, σ1Rs might be implicated 
in this process since phosphorylation of spinal ERK was attenuated in 
σ1R KO mice in a model of neuropathic pain where somatic hypersen-
sitivity was induced by peripheral nerve injury [24,51]. Although these 
evidences, in the present experimental conditions we did not detect 
changes in ERK phosphorylation neither at the acute nor the chronic 
phase of colitis, regardless the genotype considered. This might suggest 
the involvement of different mechanisms, with different involvement of 
ERK and/or different kinetics in the phosphorylation process, as it re-
lates to the development of sensitization during inflammatory and 
neuropathic pain. 
In summary, the present data show that σ1Rs play a minor role in 
modulating intestinal (colonic) inflammation. Although some molecular 
markers of inflammation were attenuated in σ1R KO mice, these changes 
did not translate in an evident clinical improvement and only correlated 
with a moderate reduction in submucosal edema. As expected, inflam-
mation was associated to the development of hypersensitivity, likely of 
both somatic and visceral origin. These pain-related alterations were 
attenuated in σ1R KO mice, thus confirming a role of σ1Rs in the 
development of hypersensitivity. Overall, these observations suggest 
that σ1Rs might represent a feasible target for the treatment of hyper-
sensitivity associated to intestinal inflammation. 
Fig. 9. (A) Representative Western blots showing tERK (left) and pERK (right) in the different experimental groups. (B) Relative spinal expression of tERK (left) and 
pERK (right). Data are mean ± SEM of n = 6 animals per group. 
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